Aziyo Biologics, which makes regenerative medical products for various tissue types, filed on Monday with the SEC to raise up to $58 million in an initial public offering.
Through its proprietary tissue processing platforms, the company has developed a portfolio of advanced regenerative medical products designed to be similar to natural biological material. Its core products are designed to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets.
The Silver Spring, MD-based company was founded in 2015 and booked $42 million in revenue for the 12 months ended June 30, 2020. It plans to list on the Nasdaq under the symbol AZYO. Aziyo Biologics filed confidentially on July 10, 2020. Piper Sandler, Cowen, Cantor Fitzgerald and Truist Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
